Want to see DMAC full AI Analyst Report?
DMAC Stock Chart & Stats
$6.74
$0.07(0.97%)
At close: 4:00 PM EDT
$6.74
$0.07(0.97%)
Day’s Range― - ―
52-Week Range$5.14 - $10.42
Previous CloseN/A
Volume23.88K
Average Volume (3M)233.78K
Market Cap
$351.60M
Enterprise Value$336.10
Total Cash (Recent Filing)$43.50M
Total Debt (Recent Filing)$185.00K
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Nov 18, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding53,925,697
10 Day Avg. Volume180,430
30 Day Avg. Volume233,782
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)6.66
Price to Sales (P/S)0.00
P/FCF Ratio-12.85
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.00Price Target Upside92.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance SheetVery low debt and meaningful equity give Diamedica durable financial flexibility to fund clinical programs without heavy interest burdens. A conservatively levered balance sheet reduces refinancing risk, supports continued R&D investment, and makes the company a more attractive partner for collaborations.
Preeclampsia Efficacy SignalRobust, statistically significant maternal blood pressure reductions and PD signals indicate a credible therapeutic effect for preeclampsia. Such durable clinical pharmacology evidence can materially de‑risk development, strengthen regulatory discussions, and improve prospects for licensing or partner interest.
ReMEDy2 Enrollment ProgressProgress toward the prespecified interim efficacy trigger and broad multinational site coverage increase the likelihood of a timely readout and provide clearer binary value inflection points. A near-term interim analysis can materially reduce development uncertainty and enhance partnering or follow‑on funding options.
Bears Say
Rising Cash Burn / Negative FCFPersistent and increasing negative free cash flow creates a structural financing need. Continued burn at current levels makes the company reliant on external capital or partnerships, elevating dilution risk and potentially constraining the pace or scale of future trials if additional funding is delayed or costly.
Pre‑revenue, Widening LossesAs a development‑stage biotech with no commercial sales, Diamedica depends entirely on financing or collaborations. Widening losses erode equity and increase the frequency or size of future funding rounds, which can dilute shareholders and complicate long‑term capital planning for multiple programs.
Additional Regulatory Preclinical WorkRegulatory requests for new preclinical studies add structural timeline and cost risk. Required animal PK/pharmacology data delay U.S. IND progress, raise development expense, and can shift regulatory sequencing, which may push back pivotal studies and dampen near‑term partnership or commercial planning.
Diamedica Therapeutics News
DMAC FAQ
What was Diamedica Therapeutics Inc’s price range in the past 12 months?
Diamedica Therapeutics Inc lowest stock price was $5.14 and its highest was $10.42 in the past 12 months.
What is Diamedica Therapeutics Inc’s market cap?
Diamedica Therapeutics Inc’s market cap is $351.60M.
When is Diamedica Therapeutics Inc’s upcoming earnings report date?
Diamedica Therapeutics Inc’s upcoming earnings report date is Nov 18, 2026 which is in 87 days.
How were Diamedica Therapeutics Inc’s earnings last quarter?
Diamedica Therapeutics Inc released its earnings results on Aug 10, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.201 by $0.011.
Is Diamedica Therapeutics Inc overvalued?
According to Wall Street analysts Diamedica Therapeutics Inc’s price is currently Undervalued.
Does Diamedica Therapeutics Inc pay dividends?
Diamedica Therapeutics Inc does not currently pay dividends.
What is Diamedica Therapeutics Inc’s EPS estimate?
Diamedica Therapeutics Inc’s EPS estimate is -0.21.
How many shares outstanding does Diamedica Therapeutics Inc have?
Diamedica Therapeutics Inc has 53,925,697 shares outstanding.
What happened to Diamedica Therapeutics Inc’s price movement after its last earnings report?
Diamedica Therapeutics Inc reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.201. Following the earnings report the stock price went up 3.308%.
Which hedge fund is a major shareholder of Diamedica Therapeutics Inc?
Currently, no hedge funds are holding shares in DMAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Diamedica Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (92.88% Upside)
$13.00 (92.88% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
43.00%
Trailing 12-Months
Company Description
Diamedica Therapeutics Inc
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
DMAC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted meaningful clinical progress: completion of the first FGR cohort, a supportive Part 1a preeclampsia data set with statistically significant blood pressure reductions and improved uterine perfusion signals, regulatory advances in Canada and planned expansions, and continued progress toward the ReMEDy2 interim analysis with broad site coverage. Financially, the company maintains a cash runway through 2027 but is experiencing a notable decline in cash and working capital versus year-end and materially higher R&D spend and operating cash burn. Operational and regulatory headwinds include enrollment variability, additional rat studies required for a U.S. IND, and a nonlinear dose-response that constrains higher-dose strategies. Overall, the positive clinical momentum and defined regulatory paths outweigh the financing and operational challenges in the near term.View all DMAC earnings summariesDMAC Stock 12 Month Forecast
Average Price Target
$13.00
▲(92.88% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Rocket Pharmaceuticals
―
Benitec Biopharma
―
Annexon Biosciences
―
Ownership Overview
17.81% Insiders
2.85% Mutual Funds
― Other Institutional Investors
75.35% Public Companies and
Individual Investors